Page 30 - Solid Tumors News Today

FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023STAMFORD, Conn., June 05, 2023 -- SpringWorks Therapeutics, Inc. , a... | June 5, 2023

Press Release ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors ... | June 5, 2023

CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a... | June 5, 2023

Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month improvement in median overall survival in patients treated with...

– Trodelvy – the First Trop-2-Directed ADC – Delivers a Durable and Clinically Meaningful 3.3 Month Improvement in Median Overall Survival vs. Comparator Chemotherapy in Phase 3... | June 5, 2023

Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive...

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

Biliary tract cancers have become the model for precision oncology because of its complex molecular landscape.

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone ... | June 3, 2023